A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in Relapse or Refractory Childhood Acute Lymphoblastic Leukemia and Lymphoma Subjects

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 07 Feb 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs BinD 19 (Primary)
Indications B-cell lymphoma; Follicular lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions
Sponsors Shenzhen BinDeBio

03 Feb 2021 Planned End Date changed from 30 Dec 2020 to 30 Dec 2021.
03 Feb 2021 Planned primary completion date changed from 30 Jun 2020 to 30 May 2021.
03 Feb 2021 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com